J&J submits 'breakthrough' cancer drug; Mass General researchers press on with diabetes drug research;

@FierceBiotech: Novo Nordisk's diabetes combo beats Lantus in Phase III. Report | Follow @FierceBiotech

@JohnCFierce: UPDATED: Patriots owner Kraft teams up on a $30M antibiotics A round for Spero. News | Follow @JohnCFierce

@DamianFierce: $TEVA chief Erez Vigodman signs his letters to $MYL with initials only, such is his commitment to synergies. | Follow @DamianFierce

> Researchers from Massachusetts General Hospital are pressing forward with a Phase II study that will test whether a long-used tuberculosis vaccine can treat Type 1 diabetes. More

> Johnson & Johnson ($JNJ) and partner Genmab have submitted the multiple myeloma treatment daratumumab to the FDA, taking advantage of the agency's breakthrough-therapy program in hopes of a speedy approval. News

Medical Device News

@FierceMedDev: ICYMI Friday: Medtronic aims for diabetic consumer tech in deals with Samsung, Glooko and connected MiniMed clearance. Article | Follow @FierceMedDev

@VarunSaxena2: 'Heart in a Box' for preserving transplanted organs received $20M in funding. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: NICE sings a different tune for Bayer's prostate cancer drug Xofigo. Story | Follow @EmilyWFierce

> Medtronic touts data in support of FDA approval of the latest MiniMed glucose monitor. Story

> Alibaba founder pumps $142M into Beijing-based devicemaker. Article

Pharma News

@FiercePharma: Are European investors catching on to the value of animal health? FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA warning letter says Czech company shipped bacteria contaminated APIs to the U.S. Article | Follow @EricPFierce

@CarlyHFierce: U.K. cost watchdogs boost J&J's Stelara ahead of hefty competition. More | Follow @CarlyHFierce

> Could an $18.9B Shire bid convince Actelion to ditch its independence? Story

> Orphan drugmaker Sobi tells potential buyer to take a walk. Article

Animal Health News

> USDA says deadly avian flu virus on the wane in the Midwest as weather warms. Report

> Nexvet shares rebound on positive data from study of pain drug in cats. Item

> FDA launches safety investigation of controversial raw foods for pets. More

> Cancer immunotherapy tried in pet dogs moves to human trials. Story

> Eli Lilly, Zoetis among stakeholders signing on to White House antibiotics plan. Article

Biotech IT News

> Amazon, Google duke it out for control of cloud genomics. Story

> 10X Genomics poaches David Jaffe from the Broad Institute. Item

> U.K. overrun by requests to opt-out of health data sharing program. Article

> Saama raises $35M to fuel push into life science data analytics. News

> Illumina misses out as U.K. picks interpretation providers for 100K Genomes Project. Report

Pharma Marketing News

> ADA highlights: Novo, Lilly meds top Lantus; Sanofi, AZ tout new combo regimens. More

> Pfizer apologizes to U.K. docs as Lyrica protection campaign hits snag. Report

> AbbVie, J&J gallop toward first-line Imbruvica sales with new survival data. Story

> Never too old to be young, Pfizer says, with new tack on Get Old campaign. Article

> Five digital campaigns that show pharma really can do it. Feature

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

The series A gives ex-Roche VP George Garibaldi a chance to realize the potential of assets that fell by the wayside at the Swiss pharma.

A host of top-suite venture capitalist firms have helped put together a meaty series A for an immuno-oncology biotech 2.0.

In the summer, Arena Pharmaceuticals hired Chris Cabell, M.D., as it chief medical officer, senior vice president and head of R&D, but now he’s out.